A system of insolvency prediction for industrial companies using a financial alternative model with neural networks

En la literatura contable, encontramos el uso de redes neuronales (NN) para predecir datos de insolvencia del último año financiero antes de la quiebra, con una tasa de éxito inferior al 85%. El objetivo de este trabajo es aumentar el poder predictivo de los modelos de NN para discriminar entre empresas solventes e insolventes, incorporando con este propósito un nuevo conjunto de ratios financieros. Una muestra de alrededor de 500 empresas industriales europeas que se declararon en quiebra entre 2007 y 2009 se enfrentó a aproximadamente 500 empresas solventes, emparejadas entre ellas por año, país y tamaño de activos. Para ello, hemos utilizado cinco conjuntos de datos de entrada diferentes para entrenar las NN. Para cada conjunto de entrada, se entrenaron 20 NN para cada número de neuronas en la capa oculta, desde 1 hasta 50 neuronas, dando un total de 5,000 NN entrenadas. El modelo propuesto predice correctamente el 92.5 y el 92.1 por ciento de las estimaciones del conjunto de entrenamiento y del conjunto de prueba (precisión), respectivamente, utilizando información financiera de dos años antes de la quiebr

Sovereign Debt and Currency Crises Prediction Models Using Machine Learning Techniques.

This research was funded by Cátedra de Economía y Finanzas Sostenibles, Universidad de Málaga, Spain. Partial funding for open access charge: Universidad de MálagaSovereign debt and currencies play an increasingly influential role in the development of any country, given the need to obtain financing and establish international relations. A recurring theme in the literature on financial crises has been the prediction of sovereign debt and currency crises due to their extreme importance in international economic activity. Nevertheless, the limitations of the existing models are related to accuracy and the literature calls for more investigation on the subject and lacks geographic diversity in the samples used. This article presents new models for the prediction of sovereign debt and currency crises, using various computational techniques, which increase their precision. Also, these models present experiences with a wide global sample of the main geographical world zones, such as Africa and the Middle East, Latin America, Asia, Europe, and globally. Our models demonstrate the superiority of computational techniques concerning statistics in terms of the level of precision, which are the best methods for the sovereign debt crisis: fuzzy decision trees, AdaBoost, extreme gradient boosting, and deep learning neural decision trees, and for forecasting the currency crisis: deep learning neural decision trees, extreme gradient boosting, random forests, and deep belief network. Our research has a large and potentially significant impact on the macroeconomic policy adequacy of the countries against the risks arising from financial crises and provides instruments that make it possible to improve the balance in the finance of the countries

Calidad de vida en pacientes oncológicos un año después de finalizado el tratamiento

Objetive: To describe the Quality of Life (QL) parameters one year after than the onco¬logy treatment was finished. Methods: 53 patients were assessed using semi-structured interviews, standardized ques¬tionnaires and records covered by the patient and doctor. Results: The total scores of QL were high. However, a high prevalence of chronic symptoms as pain (39.6%), fatigue (37.7%), sleep disturbances (32.1%), lost of appetite (18.9%) and depressing mood (41.4%) was described by the patients. Moreover, the emo¬tional state, daily life and leisure activities were the aspects of the patients life more affected through that year. Conclusions: The total score of QL is an unspecific figure but no the others variables that have a great effect on the oncology pa¬tient through the treatment. On these specific variables intervention are required.Objetivo: Describir los parámetros y los predictores de la CV un año después de finalizado el tratamiento oncológico. Método: Se evaluaron un total de 53 pacientes mediante entrevistas semiestructuradas, cuestionarios estandarizados y autoregistros cumplimentados por el paciente y el médico. Resultados: Las valoraciones generales de calidad de fueron altas. Se encontró una alta prevalencia de síntomas experimentados de forma continua como el dolor (39,6%), cansancio (37,7%), alteraciones del sueño (32,1%) y perdida de apetito (18,9%). El estado de ánimo deprimido fue referido por un 41,4% de los pacientes. Los cambios emocionales, en las actividades domésticas y en el ocio fueron los aspectos más alterados de la rutina del paciente. En las valoraciones de CV realizadas por el paciente y el médico influyeron diversas y distintas variables. Conclusiones: Las valoraciones globales de CV son puntuaciones inespecíficas mientras que son aspectos concretos y distintos en cada momento del proceso oncológico los que afectan a la CV de los pacientes y sobre los que se requerirían intervenciones específicas

Stretching the design: extending analytical circuit design from the linear to the nonlinear domain

In the design of most electronic circuits and systems, designers use computer-aided design (CAD) tools to guide the design flow. They exploit the ability of CAD tools to perform algebraic operations to compute/ predict circuit and system performance. This is possible because, in most electronic circuits and systems, linear operation can be assumed. The behavior of microwave components, circuits, and systems can, for example, be described in terms of "behavioral" parameters, such as Z-parameters, Y-parameters, and S-parameters. Transformation from one parameter to another is achieved by simple linear algebraic operations [1]. The performance of more complex circuits can be computed via linear matrix operations using the relevant parameters, i.e., Y-parameters for parallel connections and Z-parameters for series connections. More significantly, performance predictions can also be obtained via linear algebra transformations, i.e., the maximum gain, minimum noise figure, potential instability, etc., along with design insight, i.e., gain circles, noise circles, optimum input/output match requirements, and so on [1], [2].Ministerio de Ciencia e Innovación | Ref. TEC2011-29264-C03-03Ministerio de Ciencia e Innovación | Ref. TEC2011-28683-C02-0

SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)

Bladder cancer; Muscle-invasive; UrothelialCáncer de vejiga; Invasivo muscular; UrotelialCàncer de bufeta; Invasió muscular; UrotelialMost muscle-invasive bladder cancer (BC) are urothelial carcinomas (UC) of transitional origin, although histological variants of UC have been recognized. Smoking is the most important risk factor in developed countries, and the basis for prevention. UC harbors high number of genomic aberrations that make possible targeted therapies. Based on molecular features, a consensus classification identified six different MIBC subtypes. Hematuria and irritative bladder symptoms, CT scan, cystoscopy and transurethral resection are the basis for diagnosis. Radical cystectomy with pelvic lymphadenectomy is the standard approach for muscle-invasive BC, although bladder preservation is an option for selected patients who wish to avoid or cannot tolerate surgery. Perioperative cisplatin-based neoadjuvant chemotherapy is recommended for cT2-4aN0M0 tumors, or as adjuvant in patients with pT3/4 and or pN + after radical cystectomy. Follow-up is particularly important after the availability of new salvage therapies. It should be individualized and adapted to the risk of recurrence. Cisplatin–gemcitabine is considered the standard first line for metastatic tumors. Carboplatin should replace cisplatin in cisplatin-ineligible patients. According to the EMA label, pembrolizumab or atezolizumab could be an option in cisplatin-ineligible patients with high PD-L1 expression. For patients whose disease respond or did not progress after first-line platinum chemotherapy, maintenance with avelumab prolongs survival with respect to the best supportive care. Pembrolizumab also increases survival versus vinflunine or taxanes in patients with progression after chemotherapy who have not received avelumab, as well as enfortumab vedotin in those progressing to first-line chemotherapy followed by an antiPDL1/PD1. Erdafitinib may be considered in this setting in patients with FGFR alterations. An early onset of supportive and palliative care is always strongly recommended

Quality of life in cancer patients a year one year after than the treatment was finished

Objetive: To describe the Quality of Life (QL) parameters one year after than the onco¬logy treatment was finished. Methods: 53 patients were assessed using semi-structured interviews, standardized ques¬tionnaires and records covered by the patient and doctor. Results: The total scores of QL were high. However, a high prevalence of chronic symptoms as pain (39.6%), fatigue (37.7%), sleep disturbances (32.1%), lost of appetite (18.9%) and depressing mood (41.4%) was described by the patients. Moreover, the emo¬tional state, daily life and leisure activities were the aspects of the patients life more affected through that year. Conclusions: The total score of QL is an unspecific figure but no the others variables that have a great effect on the oncology pa¬tient through the treatment. On these specific variables intervention are required

Functional Proteomics Characterization of the Role of SPRYD7 in Colorectal Cancer Progression and Metastasis

SPRY domain-containing protein 7 (SPRYD7) is a barely known protein identified via spatial proteomics as being upregulated in highly metastatic-to-liver KM12SM colorectal cancer (CRC) cells in comparison to its isogenic poorly metastatic KM12C CRC cells. Here, we aimed to analyze SPRYD7’s role in CRC via functional proteomics. Through immunohistochemistry, the overexpression of SPRYD7 was observed to be associated with the poor survival of CRC patients and with an aggressive and metastatic phenotype. Stable SPRYD7 overexpression was performed in KM12C and SW480 poorly metastatic CRC cells and in their isogenic highly metastatic-to-liver-KM12SM-and-to-lymph-nodes SW620 CRC cells, respectively. Upon upregulation of SPRYD7, in vitro and in vivo functional assays confirmed a key role of SPRYD7 in the invasion and migration of CRC cells and in liver homing and tumor growth. Additionally, transient siRNA SPRYD7 silencing allowed us to confirm in vitro functional results. Furthermore, SPRYD7 was observed as an inductor of angiogenesis. In addition, the dysregulated SPRYD7-associated proteome and SPRYD7 interactors were elucidated via 10-plex TMT quantitative proteins, immunoproteomics, and bioinformatics. After WB validation, the biological pathways associated with the stable overexpression of SPRYD7 were visualized. In conclusion, it was demonstrated here that SPRYD7 is a novel protein associated with CRC progression and metastasis. Thus, SPRYD7 and its interactors might be of relevance in identifying novel therapeutic targets for advanced CRC

Spatial Proteomic Analysis of Isogenic Metastatic Colorectal Cancer Cells Reveals Key Dysregulated Proteins Associated with Lymph Node, Liver, and Lung Metastasis

Metastasis is the primary cause of colorectal cancer (CRC) death. The liver and lung, besides adjacent lymph nodes, are the most common sites of metastasis. Here, we aimed to study the lymph nodes, liver, and lung CRC metastasis by quantitative spatial proteomics analysis using CRC cell-based models that recapitulate these metastases. The isogenic KM12 cell system composed of the non-metastatic KM12C cells, liver metastatic KM12SM cells, and liver and lung metastatic KM12L4a cells, and the isogenic non-metastatic SW480 and lymph nodes metastatic SW620 cells, were used. Cells were fractionated to study by proteomics five subcellular fractions corresponding to cytoplasm, membrane, nucleus, chromatin-bound proteins, and cytoskeletal proteins, and the secretome. Trypsin digested extracts were labeled with TMT 11-plex and fractionated prior to proteomics analysis on a Q Exactive. We provide data on protein abundance and localization of 4710 proteins in their different subcellular fractions, depicting dysregulation of proteins in abundance and/or localization in the most common sites of CRC metastasis. After bioinformatics, alterations in abundance and localization for selected proteins from diverse subcellular localizations were validated via WB, IF, IHC, and ELISA using CRC cells, patient tissues, and plasma samples. Results supported the relevance of the proteomics results in an actual CRC scenario. It was particularly relevant that the measurement of GLG1 in plasma showed diagnostic ability of advanced stages of the disease, and that the mislocalization of MUC5AC and BAIAP2 in the nucleus and membrane, respectively, was significantly associated with poor prognosis of CRC patients. Our results demonstrate that the analysis of cell extracts dilutes protein alterations in abundance in specific localizations that might only be observed studying specific subcellular fractions, as here observed for BAIAP2, GLG1, PHYHIPL, TNFRSF10A, or CDKN2AIP, which are interesting proteins that should be further analyzed in CRC metastasis.This research was funded by the Instituto de Salud Carlos III (ISCIII) through the PI20CIII/00019 grants from the AES-ISCIII program to R.B., co-financed by the European Development Regional Fund “A way to achieve Europe” (FEDER). J. Hofkens. acknowledges financial support from the Research Foundation–Flanders (FWO, grant No. ZW15_09-G0H6316N), the Flemish government through long-term structural funding Methusalem (CASAS2, Meth/15/04), and the MPI as MPI fellow. S.R. acknowledges the financial support of the KU Leuven through the internal C1 funding (KU Leuven (C14/16/053)). G.S.-F. is the recipient of a predoctoral contract (grant number 1193818N) supported by The Research Foundation–Flanders (FWO). The FPU predoctoral contract to A.M.-C. is supported by the Spanish Ministerio de Educación, Cultura y Deporte.S

Los Poyos del Molinillo (Frigiliana): new site of the Bronze Age in the East Axarquía (Málaga, Andalucía)

En este trabajo damos a conocer un nuevo yacimiento descubierto recientemente en el municipio de Frigiliana. La delimitación del área denominada Los Poyos del Molinillo permitió definir la existencia de un poblado y una covacha con restos de una inhumación. El estudio de los materiales arqueológicos, que incluye cerámica, piezas metálicas o elementos de molturación, o la datación AMS obtenida, permiten adscribir el yacimiento a la Edad del Bronce y ampliar el conocimiento de esta etapa en la Axarquía oriental (Málaga, Andalucía).In this work we present a new site recently discovered in the Frigiliana municipality (Málaga). The spatial delimitation of the so called Los Poyos del Molinillo area let us define a Bronze age settlement and an inhumation burial cave. The archaeological record includes ceramic, metallic items or grinding elements, all of them belonging to the Bronze Age, as well as an AMS Radiocarbon data. This site extends the knowledge about this period in the Eastern Axarquía (Málaga, Andalucía)

Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors

AbstractBackgroundPatients with coronary heart disease (CHD) without classical cardiovascular risk factors (CRFs) are uncommon, and their profile has not been thoroughly studied. In CHD patients, we have assessed the differences in several biomarkers between those with and without CRF.MethodsWe studied 704 patients with CHD, analyzing plasma levels of biomarkers related to inflammation, thrombosis, renal damage, and heart failure: high-sensitivity C-reactive protein (hs-CRP), monocyte chemoattractant protein-1 (MCP-1), galectin-3, N-terminal fragment of brain natriuretic peptide (NT-pro-BNP), calcidiol (vitamin D metabolite), fibroblast growth factor-23 (FGF-23), parathormone, and phosphate.ResultsTwenty patients (2.8%) exhibited no CRFs. Clinical variables were well balanced in both groups, with the logical exceptions of no use of antidiabetic drugs, lower triglyceride and glucose, and higher high-density lipoprotein cholesterol in no-CRF patients.No-CRF patients showed lower hs-CRP (2.574±3.120 vs. 4.554±9.786mg/L; p=0.018), MCP-1 (114.75±36.29 vs. 143.56±65.37pg/ml; p=0.003), and FGF-23 (79.28±40.22 vs. 105.17±156.61RU/ml; p=0.024), and higher calcidiol (23.66±9.12 vs. 19.49±8.18ng/ml; p=0.025) levels. At follow-up, 10.0% vs. 11.0% patients experienced acute ischemic event, heart failure, or death in the non-CRF and CRF groups, respectively (p=0.815, log-rank test). The limited number of non-CRF patients may have influenced this finding. A Cox regression analysis in the whole population showed that high calcidiol, and low MCP-1 and FGF-23 plasma levels are associated with a better prognosis.ConclusionsCHD patients without CRFs show a favorable biomarker profile in terms of inflammation and mineral metabolism. Further studies are needed to investigate whether this difference translates into a better prognosis